Vivos Therapeutics Files Q2 2025 10-Q

TL;DR

Vivos Therapeutics filed its Q2 2025 10-Q, showing financial and operational data for the period.

AI Summary

Vivos Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2025. The company, formerly Vivos BioTechnologies, Inc., is based in Littleton, CO, and operates in the Surgical & Medical Instruments & Apparatus sector. The filing covers financial performance and business operations for the second quarter and first half of 2025, comparing it to the same periods in 2024.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for Vivos Therapeutics, crucial for understanding the company's trajectory in the medical device sector.

Risk Assessment

Risk Level: medium — As a publicly traded company filing a 10-Q, there are inherent risks associated with financial performance and market conditions.

Key Numbers

• Q2 2025 — Reporting Period (Financial and operational data for the second quarter of 2025.)
• First Half 2025 — Reporting Period (Financial and operational data for the first six months of 2025.)

Key Players & Entities

• Vivos Therapeutics, Inc. (company) — Filer of the 10-Q
• Vivos BioTechnologies, Inc. (company) — Former company name
• Littleton, CO (location) — Business address
• 20250630 (date) — Conformed period of report
• 20250819 (date) — Filed as of date

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share VVOS Nasdaq Capital Mark

Filing Documents

• form10-q.htm (10-Q) — 1067KB
• ex31-1.htm (EX-31.1) — 16KB
• ex31-2.htm (EX-31.2) — 16KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001641172-25-024832.txt ( ) — 6047KB
• vvos-20250630.xsd (EX-101.SCH) — 50KB
• vvos-20250630_cal.xml (EX-101.CAL) — 69KB
• vvos-20250630_def.xml (EX-101.DEF) — 185KB
• vvos-20250630_lab.xml (EX-101.LAB) — 372KB
• vvos-20250630_pre.xml (EX-101.PRE) — 296KB
• form10-q_htm.xml (XML) — 917KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39 PART II. OTHER INFORMATION 40 Item 1.

Legal Proceedings

Legal Proceedings 40 Item 1A.

Risk Factors

Risk Factors 41 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 45 Item 3. Defaults Upon Senior Securities 45 Item 4. Mine Safety Disclosures 45 Item 5. Other Information 45 Item 6. Exhibits, Financial Statement Schedules 45

Signatures

Signatures 46 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Report") contains "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that reflect our current expectations and views of future events. The forward-looking statements are contained principally in the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations." Readers are cautioned that known and unknown risks, uncertainties and other factors, including those over which we may have no control and others listed in this Report and our other public filings, may cause our actual results, performance or achievements to be materially different from those expressed or implied by the

forward-looking statements

forward-looking statements. You can identify some of these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. We have based these forward-looking results of operations, business strategy and financial needs. These forward-looking statements include statements relating to: our ability to continue to refine and execute our evolving business plan, including establishing and growing our new sales, marketing and distribution model where we acquire or create contractual alliances with operators of sleep testing and treatment centers as a means of driving sales of our appliances, including our June 2025 acquisition of The Sleep Center of Nevada ("SCN"); our ability to implement and grow our sales, marketing distribution model, which is new and unproven and may not produce the benefits we anticipate; our ability to successfully integrate SCN business into our operations; our ability to service the substantial indebtedness we incurred in connection with financing the SCN acquisition; compliance with laws, rules and regulations relating to the corporate practice of medicine; the acceptance and adoption by dentists, sleep specialists, medical doctors and other healthcare professionals of our proprietary oral appliances as a treatment for dentofacial abnormalities and/or mild to severe obstructive sleep apnea ("OSA") and snoring in adults and moderate to severe OSA in children ages 6-17 as per our U.S. Food and Drug Administration (or FDA) clearances; our expectations concerning the effectiveness and duration of treatment using our appliances and protocols (which we refer to as The Vivos Method) and the potential for side effects including, but not limited to, patient

View Full Filing

View this 10-Q filing on SEC EDGAR